Computer-Simulated Conversion from Intravenous to Sustained-Release Oral Theophylline

A computer equipped with a pharmacokinetic program was used to theoretically determine the proper time to administer the first dose of a commonly prescribed, sustained-release oral theophylline product (Theo-Dur) in patients maintained on a continuous intravenous aminophylline infusion. Four conversion methods were tested. They included giving the first oral dose (1) immediately upon discontinuation of the iv infusion, (2) two hours after discontinuing the iv infusion, (3) four hours after discontinuing the iv infusion, and (4) two hours before discontinuing the iv infusion. Each of the four methods was simulated in three groups of patients: Smokers, nonsmokers, and patients with cirrhosis. Results showed that, in most situations, giving the first oral dose immediately upon discontinuation of the intravenous infusion provided minimal deviation from eventual steady-state levels. In addition, this computer simulation suggests that the initial 12-hour maintenance dose recommended by the FDA may result in toxicity in certain patient groups.

[1]  J. E. Murphy,et al.  Criticism of FDA recommendations for theophylline dosage. , 1980, New England Journal of Medicine.

[2]  L. Hendeles,et al.  Avoidance of Adverse Effects during Chronic Therapy with Theophylline , 1980, European journal of respiratory diseases. Supplement.

[3]  D. Niewoehner,et al.  Efficacy of theophylline in "irreversible" airflow obstruction. , 1980, Annals of internal medicine.

[4]  I.V. dosage guidelines for theophylline products. , 1980, FDA drug bulletin.

[5]  L. Lesko,et al.  Dose-dependent Elimination Kinetics of Theophylline , 1979, Clinical pharmacokinetics.

[6]  J. Krischer,et al.  PHARMACOKINETICS OF THEOPHYLLINE: A TWO‐COMPARTMENT INSTRUCTIONAL MODEL , 1979 .

[7]  L. Hendeles,et al.  Guidelines for avoiding theophylline overdose. , 1979, The New England journal of medicine.

[8]  L. Hendeles,et al.  The relation of product formulation to absorption of oral theophylline. , 1978, The New England journal of medicine.

[9]  J. Bigley,et al.  Sustained-release theophylline therapy for chronic childhood asthma. , 1978, Pediatrics.

[10]  L. Hendeles,et al.  Monitoring Serum Theophylline Levels , 1978, Clinical pharmacokinetics.

[11]  R. Ogilvie.  Clinical Pharmacokinetics of Theophylline , 1978, Clinical pharmacokinetics.

[12]  L. Hendeles,et al.  Disposition of theophylline after a single intravenous infusion of aminophylline. , 1978, The American review of respiratory disease.

[13]  W. Jusko,et al.  Pharmacokinetics of theophylline in hepatic disease. , 1978, Chest.

[14]  L. Sansom,et al.  The influence of cigarette smoking and sex on theophylline disposition. , 2015, The American review of respiratory disease.

[15]  R. Ogilvie,et al.  Theophylline disposition in patients with hepatic cirrhosis. , 1977, The New England journal of medicine.

[16]  R. Ogilvie,et al.  Theophylline kinetics in acute pulmonary edema , 1977, Clinical pharmacology and therapeutics.

[17]  W. Jusko,et al.  Effect of smoking on theophylline disposition , 1976, Clinical pharmacology and therapeutics.

[18]  H. Nagasawa,et al.  Decreased theophylline half-life in cigarette smokers. , 1975, Life sciences.

[19]  John G. Wagner,et al.  Biopharmaceutics and Relevant Pharmacokinetics , 1971 .

[20]  L. Tuft,et al.  The influence of various drugs upon allergic reactions , 1936 .

[21]  D. I. Macht,et al.  A STUDY OF ANTISPASMODIC DRUGS ON THE BRONCHUS , 1921 .